Preventing acute rejection in pediatric liver transplantation
This article has no abstract so we have provided the first paragraph of the full text.
Kelly et al. have performed the first randomized controlled trial of immunosuppression in pediatric liver transplant patients. This multicenter, open-label trial compared the efficacy of the two currently available calcineurin inhibitors—tacrolimus and ciclosporin microemulsion—in 181 children undergoing primary liver allograft transplantation at age 9–56 months.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
